84 results about "Buccal mucosa" patented technology

A vaginal or buccal delivery of therapeutic agents having a substrate affinity for metabolic cytochrome P-450 enzymes and membrane efflux transporter systems. A method for augmentation of systemic exposure to the therapeutic agents having a substrate affinity for cytochrome P-450 enzymes and membrane efflux transporter systems, by delivering said agents to the systemic circulation through vaginal or buccal mucosa.

Pharmaceutical compositions comprising a narcotic analgesic in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and other micelle-forming compounds as described in the specification. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed. A preferred method for administering the present composition is through the buccal mucosa of the mouth.

The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk (10) which has two compartments (14) and (18); the compartments consist of at least one active agent and at least one mucoadhesive agent and both the compartments are adapted to be in contact with the mucosal membrane. The invention also provides for transmucosal administration of an active agent and method of treatment of diseases in a subject in need of such treatment.

The present invention is directed to a scraping instrument for collection of a biological sample, and a non-invasive method for obtaining nucleic acid from buccal mucosa epithelial cells using the scraping instrument. Such nucleic acid can be used for example for gene expression profiling, including to assess lung disease risk associated with airway pollutants.

An orthodontic appliance that is particularly useful for correcting a class occlusion is disclosed. The appliance includes a mounting arrangement for mounting over an upper arch of a user having a front region and two arm regions extending rearward from the front region. The mounting arrangement includes an outer wall and an inner wall and a web extending there between. The outer wall, the web and the inner wall collectively define an upper channel within which the upper arch and teeth of a user are received to mount the appliance. They also define a lower channel for receiving the lower arch and teeth. The outer wall has an upper portion spaced forward of the upper arch teeth and gums forming an outer spacing formation for holding the buccal mucosa away therefrom. The appliance also includes a tongue elevator on a lower portion of the inner wall for raising position corresponding to an arch form will tend to return to the desired arch form. Further the resilient flexibility assists fitting of the appliance.

The invention relates to an oral instant membrane of risperidone and a preparation method thereof, thereby being used for improving the using performance of the risperidone. The technical scheme is as follows: the instant membrane comprises 2-60 parts by weight of risperidone, 25-98 parts by weight of water-soluble pharmaceutical polymer excipients, additives and 0.1-25 parts by weight of water. The oral instant membrane solves the problems that the existing risperidone is clinically difficult to swallow, is not applicable to children and elderly patients for administration and can not be conveniently taken under the situation of having no water. The oral instant membrane can be dissolved on the tongue, the hidden trouble of choking can not be happened no matter how young a baby is, the active ingredients can be absorbed sublingually and absorbed by buccal mucosa, and the onset of action is more rapid in comparison with orally disintegrating tablets. In addition, the oral instant membrane has good compliance, thereby being particularly suitable for elderly people, children and patients with difficult swallowing.

A keratoprosthesis and system and method of using same for corneal repair. The keratoprosthesis comprises a biocompatible support and an optic member disposed through a channel within the support. The support includes metal, preferably titanium, and treated, such as by sandblasting and/or acid etching, to create textured surfaces that promote soft tissue adhesion. A locking member interconnects the optic member and support. An outer surface of the locking member a collar extending from the support and disposed around the optic member is also metal, preferably titanium, and is similarly treated to promote soft tissue adhesion. A locking member interconnects the optic member and support. The system includes the keratoprosthesis positioned within an isolated soft tissue segment of a non-ocular tissue, such as buccal mucosa, placed on the anterior cornea. The method includes removing corneal epithelium, isolating and transplanting a segment of soft tissue to the de-epithelialized cornea, creating a receiving area in the soft tissue, positioning a keratoprosthesis relative to the receiving area anterior to the cornea, and securing the keratoprosthesis.

The invention discloses an oral protection mat suitable for oral treatment. The oral protection mat comprises a buccal mucosa protective baffle plate, a retromolar tissue protective baffle plate and atongue protective baffle plate, wherein a circle of water draining pipelines are arranged at the periphery of the tongue protective baffle plate in a surrounding way, and 6 to 8 liquid sucking holesare formed in the tongue protective baffle plate; two sides of the water draining pipelines respectively stretch outwards along a horizontal direction to form skirts; the tongue protective baffle plate is provided with a negative-pressure interface converter; one end of the negative-pressure interface converter is communicated with the water draining pipelines, and the other end is communicated with a negative-pressure pipe of an oral integrated treatment table in a joint buckling connection way. The invention also relates to a using method of the oral protection mat for the oral treatment. The using method is simple and easy, is capable of forming stable operation space in the oral cavity of a patient, effectively isolating oral treatment operation space and oral non-treatment space and removing waste liquid and saliva generated in the oral cavity of the patient in time; an accessary occlusion assembly is also cpaable of relieving muscle fatigue caused by sustained mouth opening of the patient, the working efficiency is grealty increased, and the diagnosis and treatment risks are reduced.

The invention discloses soluble fentanyl, a derivative buccal membrane preparation thereof and a preparing method thereof. The soluble fentanyl and the derivative buccal membrane preparation thereof can be instant fentanyl and a derivative buccal membrane preparation thereof, can be soluble slow-release fentanyl and a derivative buccal membrane preparation thereof and also can be instant and soluble slow-release fentanyl and a derivative buccal double-layer-membrane preparation. An instant membrane can be dissolved quickly at a buccal mucosa in one minute at the oral cavity, the fentanyl and a derivative thereof are released, and the clinical effect of efficient analgesia is achieved. A slow-release membrane slowly releases medicine within four hours in the oral cavity, and effective blood concentration is maintained for a long time. An instant-slow-release double-layer membrane has a quick effect, the medicine effect is durable, and continuous analgesia can be achieved.

The invention belongs to the technical field of biology and particularly discloses an oral cancer detection marker and an oral cancer detection kit. The levels of mRNA of CDC6, CDT1, MCM2 and CDC45 in buccal mucosal cells of a normal person, a person with oral inflammation, a person with precancerous lesions, a person with oral cancer and a person at the postoperation period are quantitatively detected, the detection shows that CDC6, CDT1, MCM2 and CDC45 are ideal tumor markers for the screening of the oral cavity in the early stage, and the normal buccal mucosal cells and the canceration exfoliated cells are effectively distinguished. The oral cancer detection marker and the oral cancer detection kit are of great significance for the exploration of the mechanism of the content change of the tumor marker in the buccal mucosal cells and the clinical value of prognosis judgement.

The invention discloses a preparation method of an animal model with oral ulcer caused by fire excess from yin deficiency. The method comprises selecting healthy rats, carrying out subcutaneous injection on the rats with a triiodothyronine solution according to the dosage of 5-200 micrograms per kilogram for 14-21 days, carrying out impregnation on a cotton ball with phenol, and firing the rat lateral buccal mucosa to form a white wound so that a desired animal model can be obtained after 24-48h. Compared with the prior art, the method is used for preparation of an animal model with oral ulcercaused by fire excess from yin deficiency. The model can induce the oral ulcer based on the fire excess from yin deficiency according to the traditional Chinese medicine differentiation of symptoms and signs, well satisfies clinical practice, has high feasibility and high applicability and has a great application value in heat and fire removal, tissue damage reduction and ulcer healing promotion.

A method of manufacturing a stable nanosuspension for delivery of a biologically active agent into the bloodstream of a subject is disclosed. A microfluidizable mixture is initially formed and processed via a microfluidization process to form the stable nanosuspension, which may be administered via the buccal mucosa or other suitable routes of administration. This product demonstrates increased bioavailability, enhanced period of onset, and enhanced stability for a controlled-release product.

Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10⁷ cells/mL.